Endoscopic Ultrasound — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Endoscopic ultrasound (EUS) is an advanced diagnostic and therapeutic modality combining flexible endoscopy with high-frequency (5–20 MHz) ultrasound imaging. A specialised echoendoscope with an ultrasound transducer at its tip is introduced into the gastrointestinal tract, positioning the transducer in immediate contact with the luminal wall — just millimetres from adjacent structures — providing dramatically higher resolution images than external abdominal ultrasound or CT scanning. EUS can visualise the layers of the GI wall in distinct detail (mucosa, submucosa, muscularis propria, adventitia/serosa), the pancreas, common bile duct, liver, left adrenal gland, coeliac axis vessels, mediastinal structures, and regional lymph nodes. The echoendoscope incorporates both end-viewing and side-viewing optical systems for simultaneous endoscopic visualisation. Radial echoendoscopes provide 360-degree transverse ultrasound imaging; linear array echoendoscopes provide real-time sector imaging that enables simultaneous needle passage for EUS-guided fine-needle aspiration (FNA) and fine-needle biopsy (FNB), the primary therapeutic application. EUS has fundamentally changed pancreatic and gastrointestinal oncology by enabling non-surgical tissue diagnosis from previously inaccessible lesions. EUS is performed by gastroenterologists with advanced endoscopy training in tertiary referral centres. It requires specialist equipment — the linear echoendoscope for FNA/FNB and the radial echoendoscope for staging assessment.

EUS is indicated for a range of diagnostic and therapeutic applications across gastroenterology, hepatology, and thoracic medicine. Oncological staging is the primary application: T and N staging of oesophageal cancer (EUS is the most accurate modality for T-staging, assessing depth of wall invasion), gastric cancer, pancreatic cancer, rectal cancer, and non-small cell lung cancer (mediastinal lymph node sampling). Pancreatic assessment covers evaluation of pancreatic masses, cystic lesions (identifying high-risk features: mural nodule, main duct dilatation, solid component), suspected chronic pancreatitis, and pancreas divisum. Biliary pathology includes common bile duct stone detection (sensitivity 89–94%, superior to MRCP for small stones), hilar cholangiocarcinoma staging, and unexplained biliary stricture. Submucosal GI lesion assessment identifies lesion layer of origin, echogenicity, size, and vascular supply for GISTs, lipomas, and carcinoid tumours. Mediastinal staging of lung cancer via EBUS (endobronchial ultrasound) or EUS provides tissue from paratracheal, subcarinal, and para-oesophageal nodes. Therapeutic EUS includes drainage of pancreatic pseudocysts and walled-off necrosis, EUS-guided biliary drainage, and coeliac plexus neurolysis for chronic pancreatitis or pancreatic cancer pain.

Patients fast for 6 hours before EUS for upper gastrointestinal procedures. Intravenous sedation (midazolam and fentanyl, or propofol at higher sedation level) is administered by the endoscopy team with monitoring of oxygen saturation, ECG, and blood pressure. The echoendoscope is passed orally (upper EUS) or via the rectum (lower EUS). For upper EUS, the instrument is advanced through the oesophagus, stomach, and duodenum in sequence, acquiring systematic ultrasound images of each region with water filling as acoustic coupling if required. The pancreatic head, uncinate process, and common bile duct are best visualised from the duodenum; the pancreatic body and tail, splenic vein, portal confluence, and coeliac axis from the gastric fundus and body. For EUS-FNA/FNB, the linear echoendoscope aligns the needle trajectory along the ultrasound beam. After Doppler confirmation that no vessels intervene, a 19–25 gauge needle is passed through the scope channel, advanced under real-time EUS guidance into the lesion, and agitated with suction to aspirate cells (FNA) or with a reverse bevel to core tissue (FNB). Multiple passes are made; the specimen is expressed onto slides or into formalin for cytology and histology. For EUS-guided drainage, the pseudocyst or biliary system is punctured and a metal or plastic stent is deployed under combined EUS and fluoroscopic guidance.

EUS-FNA/FNB achieves diagnostic accuracy of 85–95% for pancreatic masses — the highest of any non-surgical sampling technique for this indication. In a meta-analysis of 33 studies, EUS-FNA sensitivity for pancreatic malignancy was 85% with specificity of 98%. EUS-FNB using core biopsy needles improves histological diagnosis rates to 90–95%, enabling molecular profiling and immunohistochemistry necessary for targeted therapy eligibility decisions. For oesophageal cancer T-staging, EUS accuracy reaches 80–85% for T category and 75–80% for N category when combined with FNA of suspicious nodes. EUS detects choledocholithiasis with sensitivity of 89–94% and specificity of 95%, and is cost-effective for patients with intermediate probability bile duct stones before ERCP. EUS-guided coeliac plexus neurolysis provides significant pain relief in 70–80% of patients with chronic pancreatitis or pancreatic cancer for 6–10 weeks. EUS-guided pseudocyst drainage achieves technical success in over 95% of cases with clinical resolution in 85–90%, eliminating surgical intervention for this condition.

Standard EUS without biopsy is very safe, with complication rates similar to standard upper endoscopy. Risks include sedation-related adverse events (respiratory depression, aspiration), oesophageal perforation from the endoscope tip in the presence of stricture or Zenker's diverticulum (rare, <0.1%), and post-procedure abdominal discomfort and bloating. EUS-FNA adds specific procedural risks: post-procedural pancreatitis from pancreatic parenchymal FNA (0.5–1%), bleeding at the puncture site (0.5–1%), and infection particularly after cyst sampling (0.5–1%) — prophylactic antibiotics (ciprofloxacin 500 mg twice daily for 3–5 days) are given for pancreatic cyst FNA. Bile duct FNA carries risk of cholangitis (<0.5%) and haemobilia. Tumour seeding along the needle track, a concern for EUS-FNA of pancreatic cancer, is reported in very rare cases and does not influence staging decisions given the established diagnostic benefit. EUS-guided drainage carries higher risks including stent migration, haemorrhage, and perforation in experienced centres at rates of 2–5%.

After upper EUS under conscious sedation, patients are monitored in the recovery area for 1–2 hours until sedation has fully reversed and swallow and cough reflexes have returned. Vital signs and sedation level are scored at regular intervals. A driver is required to accompany the patient home — driving is not permitted on the day of the procedure due to residual sedative effects. Light fluids are permitted once the patient is fully alert; a soft diet for the remainder of the day is advised. Mild throat discomfort and bloating are common and resolve within 24 hours. If EUS-FNA of the pancreas was performed, the patient is advised to report any new or worsening abdominal pain developing 12–48 hours post-procedure — this may indicate post-procedural pancreatitis requiring assessment. Biopsy results are typically available within 5–10 working days for cytology and 7–14 days for histology, depending on laboratory processing. The referring gastroenterologist or oncologist reviews results and communicates the clinical implications and any further management plan to the patient at a follow-up appointment.